

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
Frosch, 2008 ¹	Total knowledge score/imputed data	Score unit	Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer-specific Web sites from credible sources	116		7.24			0.005
				155		8.14		0.9	
	Total knowledge score/complete cases only	Score unit	Traditional didactic decision aid providing information about prostate specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer-specific Web sites from credible sources	99		7.49			0.001
				119		8.65		1.16	
	Total knowledge score/imputed data	Score unit	Chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	116		7.24			0.005
				153		7.69		0.45	
Total	Score unit	Chronic disease	99		7.49			0.001	

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	knowledge score/complete cases only		trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	115		8.03		0.54	
	Total knowledge score/imputed data	Score unit	Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	116		7.24			0.005
				152		7.71		0.47	
	Total knowledge score/complete cases only	Score unit	Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	99		7.49			0.001
				117		8.03		0.54	
	PSA screening: Pretest choice	% of patients with outcome	Traditional didactic decision aid providing information about prostate specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer-specific Web sites from credible sources	116		96			**SNR
				155		95.5		-0.5	
	PSA	% of	Traditional didactic	116		3.3			0.047

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	screening: Reduction	patients with outcome	decision aid providing information about prostate specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer-specific Web sites from credible sources	155		9.1		5.8	
	Watchful waiting at pretest	% of patients with outcome	Traditional didactic decision aid providing information about prostate specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer-specific Web sites from credible sources	116		34.4			0
				155		34.2		-0.2	
	PSA screening: Pretest choice	% of patients with outcome	Chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	116		96			**SNR
				153		96.7		0.7	
	PSA	% of	Chronic disease	116		3.3			0.047

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	screening: Reduction	patients with outcome	trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	153		8.7		5.4	
	Watchful waiting at pretest	% of patients with outcome	Chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	116		34.4			0
				153		34		-0.4	
	PSA screening: Pretest choice	% of patients with outcome	Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	116		96			**SNR
				152		96.7		0.7	
	PSA screening: Reduction	% of patients with outcome	Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	116		3.3			0
				152		5.3		2	
	Watchful	% of	Both the didactic	116		34.4			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	waiting at pretest	patients with outcome	decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	152		40.8		6.4	
	Total knowledge score/imputed data	Score unit	Chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	116		7.24		0.45	0.005
				153		7.69			
	Total knowledge score/complete cases only	Score unit	Chronic disease trajectory model for prostate cancer followed by a time-trade-off exercise vs. Links to public prostate cancer-specific Web sites from credible sources	99		7.49		0.54	0.001
				115		8.03			
	Total knowledge score/imputed data	Score unit	Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	116		7.24		0.47	0.005
				152		7.71			
	Total	Score unit	Both the didactic	99		7.49			0.001

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	knowledge score/completed cases only		decision aid and the chronic disease trajectory model vs. Links to public prostate cancer-specific Web sites from credible sources	117		8.03		0.54	
Ruland, 2003 ²	Congruence between patient-reported symptoms and those addressed in consult visit	% congruence	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.84			<0.01
				27		7.63		4.79	
	Importance-weighted congruence between patient reported symptoms and those addressed in consult visit	% congruence	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		12.8			<0.01
			27		33		20.2		
	Number of reported symptoms (0-10)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.25			0
				27		2.73		0.48	
	Number of	Number of	Used computerized	25		2.25			0.032

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	reported symptoms (0-15)	symptoms	system for shared decisionmaking for cancer symptoms care vs. Usual care	27		3.77		1.52	
	Number of reported symptoms (0-20)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.18			0.016
				27		4.5		2.32	
	Number of reported symptoms (0-25)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.17			0.004
				27		5.28		3.11	
	Number of reported symptoms (0-30)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.17			0.017
				27		5.25		3.08	
Number of reported symptoms (0-40)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.63			0	
			27		6.56		3.93		
Number of reported symptoms (0-50)	Number of symptoms	Used computerized system for shared decisionmaking for cancer symptoms care vs. Usual care	25		2.84			0.042	
Taenzer,	Physical	Score unit	Lung cancer patients	26		76.9			<0.05

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
2000 ⁵	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		60		-16.9	
	Role	Score unit	Lung cancer patients	26		84.6			<0.01

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		55.6		-29	
	Emotional	Score unit	Lung cancer patients	26		76.3			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		75.9		-0.4	
	Cognitive	Score unit	Lung cancer patients	26		81.4			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		80.3		-1.1	
	Social	Score unit	Lung cancer patients	26		78.9			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		74		-4.9	
	Global	Score unit	Lung cancer patients	26		64.7			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	functioning (higher scores indicate better function)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		52.8		-11.9	
	Number of	Number of	Lung cancer patients	26		3			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	functional scales indicating compromised function (mean)	scales	whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		3.6		0.6	
	Fatigue	Score unit	Lung cancer patients	26		28.6			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	(higher scores indicate more symptomatology--mean)		whose physicians and nurses received quality-of-life training and patients completed the computerized EORTC QLQ-C30 vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		41.2		12.6	

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	<u>n Final Control</u>	<u>Control Outcome Measure at Baseline</u>	<u>Control Outcome Measure at Final</u>	<u>Control Change</u> Intervention Change	<u>Change Difference</u> Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final			
	Nausea and vomiting (higher scores indicate more symptomatology--mean)	Score unit	Lung cancer patients whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	26		9			0
				27		8.6		-0.4	
	Pain (higher	Score unit	Lung cancer patients	26		15.4			

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	<u>n Final Control</u> <u>n Final Intervention</u>	<u>Control Outcome Measure at Baseline</u> <u>Intervention Outcome Measure at Baseline</u>	<u>Control Outcome Measure at Final</u> <u>Intervention Outcome Measure at Final</u>	<u>Control Change</u> <u>Intervention Change</u>	<u>Change Difference</u> <u>Final Difference</u>	P-Value
	scores indicate more symptomatology--mean)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		26.5		11.1	
	Dyspnea	Score unit	Lung cancer patients	26		34.6			<0.05

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	(higher scores indicate more symptomatology--mean)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		51.9		17.3	
	Sleep	Score unit	Lung cancer patients	26		24.4			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	disturbance (higher scores indicate more symptomatology)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		29.6		5.2	
	Appetite	Score unit	Lung cancer patients	26		19.2			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	(higher scores indicate more symptomatology)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		25.9		6.7	
	Constipation	Score unit	Lung cancer patients	26		18			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	(higher scores indicate more symptomatology)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		19.8		1.8	
	Diarrhea	Score unit	Lung cancer patients	26		5.1			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	(higher scores indicate more symptomatology)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		2.5		-2.6	
	Financial	Score unit	Lung cancer patients	26		18			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control	Control Outcome Measure at Baseline	Control Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
				n Final Intervention	Intervention Outcome Measure at Baseline	Intervention Outcome Measure at Final		Final Difference	
	difficulties (higher scores indicate more symptomatology)		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		12.4		-5.6	
	Number of	Number of	Lung cancer patients	26		4			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	symptom scales indicating compromised functioning	scales	whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		4.6		0.6	
	Number of	Number of	Lung cancer patients	26		7.1			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	functional and symptom scales indicating compromised function	scales	whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	27		8.2		1.1	

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	Total number of items endorsed	Number of items	Lung cancer patients whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization for Research and Treatment of Cancer Questionnaire vs. Patients who completed a paper-and pencil version of the European Organization for Research and Treatment of Cancer Questionnaire only	26		10.6			0
	Actions	Actions	Lung cancer patients	26		0.5			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	$\frac{n \text{ Final Control}}{n \text{ Final Intervention}}$	$\frac{\text{Control Outcome Measure at Baseline}}{\text{Intervention Outcome Measure at Baseline}}$	$\frac{\text{Control Outcome Measure at Final}}{\text{Intervention Outcome Measure at Final}}$	$\frac{\text{Control Change}}{\text{Intervention Change}}$	$\frac{\text{Change Difference}}{\text{Final Difference}}$	P-Value
	taken/patient		whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization For Research And Treatment Of Cancer QLQ-C30 vs. Patients who completed a paper-and pencil version of the European Organization For Research And Treatment Of Cancer QLQ-C30 only	27		0.8		0.3	
	% of	% of	Lung cancer patients	26		64.7			0

Evidence Table 25. Outcomes related to cancer in studies addressing improving responsiveness to the needs and preferences of individual patients (continued)

Study, Year	Outcomes Measure	Unit	Description of Intervention	n Final Control n Final Intervention	Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline	Control Outcome Measure at Final Intervention Outcome Measure at Final	Control Change Intervention Change	Change Difference Final Difference	P-Value
	categories identified that were acted upon	categories	whose physicians and nurses received quality-of-life training and patients completed the computerized European Organization For Research And Treatment Of Cancer QLQ-C30 vs. Patients who completed a paper-and pencil version of the European Organization For Research And Treatment Of Cancer QLQ-C30 only	27		73		8.3	

**SNR: Significance not reported

P-value of 0 = p-value > 0.10

PSA = Prostate-specific antigen; QLQ = quality of life questionnaire

Reference List

- 1 Frosch DL, Bhatnagar V, Tally S, Hamori CJ, Kaplan RM. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening. *Arch Intern Med* 2008; 168(4):363-9.
- 2 Ruland CM, White T, Stevens M, Fanciullo G, Khilani SM. Effects of a computerized system to support shared decision making in symptom management of cancer patients: preliminary results. *Journal of the American Medical Informatics Association : JAMIA* 2003; 10(6):573-9.
- 3 Taenzer P, Bultz BD, Carlson LE *et al.* Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. *Psychooncology* 2000; 9(3):203-13.